Alvameline

Alvameline

Clinical data
ATC code	None
Identifiers
IUPAC name 3-(2-ethyltetrazol-5-yl)-1-methyl-5,6-dihydro-2H-pyridine
CAS Number	120241-31-8  Y
PubChem CID	178030
ChemSpider	154980  Y
UNII	4XFD7B36M6
ChEMBL	ChEMBL131428  Y
CompTox Dashboard (EPA)	DTXSID30152748
Chemical and physical data
Formula	C9H15N5
Molar mass	193.254 g·mol−1
3D model (JSmol)	Interactive image
SMILES n1nn(nc1\C2=C\CCN(C)C2)CC
InChI InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3 Y Key:RNMOMKCRCIRYCZ-UHFFFAOYSA-N Y
(verify)

Alvameline (Lu 25-109) is a M₁ receptor agonist and M₂/M₃ receptor antagonist ^[1] that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials ^[2] and was subsequently discontinued.

See also

• Milameline
• Sabcomeline
• Tazomeline
• Xanomeline

References

1. Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J (June 1998). "In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro". Psychopharmacology. 137 (3): 233–240. doi:10.1007/s002130050615. PMID   9683000. S2CID   20740372. Archived from the original on 2000-10-02. Retrieved 2009-12-03.
2. Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR (1998). "A bridging study of LU 25-109 in patients with probable Alzheimer's disease". Life Sciences. 62 (3): 195–202. doi:10.1016/S0024-3205(97)01087-4. PMID   9488097.